Key result
Combination chemotherapy for osteogenic sarcoma was associated with an unusual neurological syndrome of abrupt focal cerebral deficits in 4 of 158 patients.
Observational (n=158)
Combination chemotherapy with vincristine and high-dose methotrexate for osteogenic sarcoma may be associated with a transient neurological syndrome characterized by focal cerebral deficits.
Answers are grounded in this paper and cite their sources.
Warrants monitoring for focal deficits during osteogenic sarcoma chemotherapy; leaves open causality and incidence.
An unusual neurological syndrome occurred in 4 of 158 patients treated for osteogenic sarcoma with combination chemotherapy. There was an abrupt onset of focal cerebral deficits approximately ten days after chemotherapy with vincristine and high‐dose methotrexate plus citrovorum factor rescue. The syndrome was short lived and always occurred early in the course of treatment. Prolonged neurological deficits remained in 2 patients. When similar chemotherapy was reinstituted in the 4 patients, no further neurological complications ensued. Possible causes include a leukoencephalopathy related to methotrexate or an embolic cerebral vasculopathy related to necrotic tumor microemboli emanating from the lungs.
No takes yet. Share an insight, caveat, or question.
Allen et al. (1978) conducted an observational in Osteogenic sarcoma (n=158). Combination chemotherapy (vincristine, high-dose methotrexate, citrovorum factor rescue) was evaluated on Unusual neurological syndrome (focal cerebral deficits). Combination chemotherapy for osteogenic sarcoma was associated with an unusual neurological syndrome of abrupt focal cerebral deficits in 4 of 158 patients.
Synapse has enriched 10 related papers. Consider them for comparative context: